Drug intelligence / Profile preview

EN3001

Development stage: Preclinical
Lead developer: Enosi Life Sciences

Overview

EN3001 is a preclinical biologic antagonist of tumor necrosis factor receptor 2 (TNFR2) being developed by Enosi Life Sciences for autoimmune diseases, cancer, and fibrotic conditions. By selectively inhibiting TNFR2, which is overexpressed in many tumors and drives expansion of immunosuppressive regulatory T cells, EN3001 is intended to act functionally as a checkpoint inhibitor and enhance antitumor immunity while modulating pathogenic inflammation. The molecule is part of Enosi’s TNF pathway–targeted pipeline and remains several years away from clinical testing, with detailed structural modality (e.g., antibody vs fusion protein) not yet fully disclosed.

Other names: EN-3001EN3001EN 3001

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)

Beyond the preview

Go deeper on EN3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EN3001.

Explore the full profile